All In Biotech

Drug Trial Radar · NCT05515367

A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)

A Phase 4,52 Week, Single Arm,Multicentre Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).

Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,004

Planned (sponsor's estimate)

Start

Apr 20, 2023

Primary completion

Jun 30, 2025

Study completion Nov 30, 2025

Sponsor

Lead sponsor
Zydus Lifesciences LimitedIndustry
Sponsor type
Industry
First posted
Aug 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 4, 52 week, single arm, multicentre post marketing surveillance to evaluate the safety of Desidustat for the treatment of anemia in subjects with chronic kidney disease (CKD)

Conditions

  • Chronic Kidney Diseases
  • Anemia of Chronic Kidney Disease

Interventions

  • DesidustatDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To asses the Proportion of Subjects with treatment emergent adverse events.Time frame: Baseline (week 0) to Week 52 (end of treatment)
  2. To asses the Proportion of Subjects with treatment emergent Serious adverse events.Time frame: Baseline (week 0) to Week 52 (end of treatment)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Indira Gandhi Institute of Medical Sciences

    Sheikhpura, Bihar, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.